Trials / No Longer Available
No Longer AvailableNCT04052854
A Single-Arm, Expanded Access Study of Zanubrutinib in Participants With B-cell Malignancies
A Single-Arm, Expanded Access Study of Zanubrutinib (BGB3111) in Participants With B-cell Malignancies
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- BeiGene · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
This is a multicenter expanded access study of zanubrutinib monotherapy for participants with B-cell malignancies who are ineligible to enroll into any available zanubrutinib clinical trials
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Zanubrutinib | Zanubrutinib will be orally administered in participants with treatment naive or R/R WM |
Timeline
- First posted
- 2019-08-12
- Last updated
- 2024-10-23
Locations
10 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT04052854. Inclusion in this directory is not an endorsement.